Loading...

PCRX PACIRA BIOSCIENCES INC Legal Disputes 8-K Filing

PCR

PCRX

PACIRA BIOSCIENCES INC

(PCRX)

2025 8-K

Show Summary

Show Summary

Stock Incentive Plan Approval

Financial Statements

Share Repurchase

Patent Settlement

Bylaw Amendments

Financial Results

Management Changes

Revenue Announcement

Financial Results & Changes

Management Change

Management Changes

Board Resignation

Earnings Report

Retirement of Director

Merger of Equals

Quantitative Data

Financial Results and Share...

Financial Results and CFO D...

Earnings Announcement

Appointment of CEO and Empl...

Financial Results Announcement

Appointment of Directors

Earnings Report

Annual Meeting Approval

Earnings Release

Credit Agreement Refinancin...

Departure of Directors

Earnings Announcement

Earnings Report

External Links:

On April 7, 2025, Pacira BioSciences entered into a Settlement Agreement with Fresenius Kabi and others regarding patent infringement suits for EXPAREL, allowing limited generic production starting in early 2030 and involving a $7 million payment to

AI Assistant

PACIRA BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.